- Molecular NameRoxithromycin
- SynonymNA
- Weight837.058
- Drugbank_IDDB00778
- ACS_NO80214-83-1
- Show 3D model
- LogP (experiment)3.79
- LogP (predicted, AB/LogP v2.0)3.42
- pkaN/A
- LogD (pH=7, predicted)1.86
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.58
- LogSw (predicted, AB/LogsW2.0)0.21
- Sw (mg/ml) (predicted, ACD/Labs)0.19
- No.of HBond Donors5
- No.of HBond Acceptors17
- No.of Rotatable Bonds13
- TPSA216.89
- StatusFDA approved
- AdministrationN/A
- PharmacologyA semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections.
- Absorption_valueN/A
- Absorption (description)Very rapidly absorbed and diffused into most tissues and phagocytes.
- Caco_2N/A
- Bioavailability50.0
- Protein binding96.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged. Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites. The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces.
- Half life8~13 h (prolonged in patients with hepatic and renal impairment); 20 to 21 h in children aged <18 months to 13 years.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityMost common side-effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.
- LD50 (rat)N/A
- LD50 (mouse)N/A